PT-141 · RESEARCH BRIEF
PT-141 Peptide: What It Is and What to Buy
On this page +
PT-141 peptide is bremelanotide, a lab-made peptide studied for melanocortin receptor signaling: how cells respond to a particular family of chemical signals. For a research order specifying PT-141, choose a PT-141 vial, not Melanotan II simply because the names appear together online. Mytide sells the freeze-dried research material. It is not Vyleesi, the prescription medicine containing bremelanotide, and is not a substitute for it.
- PT-141 and bremelanotide are names for the same compound; Vyleesi is a distinct prescription product.
- PT-141 and Melanotan II are separate compounds and are not interchangeable.
- Published research examines melanocortin receptor activity; clinical findings for a prescription formulation do not establish the properties or suitability of a research vial.
- Compare product identity, the listed amount and the available batch-specific analytical documentation before ordering.
- Mytide products are for laboratory research only, not human or animal consumption.
What is PT-141 and where did it come from?
PT-141 is a synthetic melanocortin peptide also known as bremelanotide. It is related to alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring signaling peptide. The names PT-141 and bremelanotide identify the compound; they do not identify a specific finished product or establish that a research material is a medicine. Molinoff and colleagues described the compound and its receptor activity.
PT-141, bremelanotide and Vyleesi
Bremelanotide is the compound name; PT-141 is a research designation. Vyleesi is a particular FDA-approved prescription product containing bremelanotide. Its approval does not extend to Mytide's research vial. The distinction is documented in the FDA review. The two products are not interchangeable.
Reported mechanism of action
Melanocortin receptor signaling
Receptors are proteins that respond to chemical signals. PT-141 is a melanocortin receptor agonist, meaning it can activate members of that receptor family. Published work identifies activity at MC3 and MC4 receptors; the FDA review also discusses other receptor subtypes. Activity at a receptor is a laboratory observation, not proof of a particular outcome in every experimental system. FDA multidisciplinary review.
Receptor selectivity and context
The receptor family has several subtypes. A compound that interacts with more than one subtype is not accurately described as acting exclusively on one receptor. Cell type, assay method and receptor expression all matter when interpreting a result. Binding measurements and downstream biological responses are different endpoints, so results should be compared only in the context of the methods used.
Central nervous system research
MC3 and MC4 receptors are found primarily in the central nervous system, according to the published PT-141 overview. That finding helps explain why researchers study melanocortin pathways, but it does not establish that a particular vial has been assessed for any clinical use.
What the research literature examines
Receptor pharmacology
Researchers have examined PT-141 as a tool for studying melanocortin receptor signaling and differences between receptor subtypes. The FDA's review summarizes receptor binding and nonclinical pharmacology for bremelanotide. An assay result describes that assay and does not by itself establish safety, performance or identity for an unrelated batch.
Preclinical behavioral models
A 2004 study in a rat model examined behavioral responses to PT-141. Its findings are specific to the animals, measurements and conditions studied. They are not evidence of a personal benefit, and they do not establish how a Mytide product would behave in a different experiment.
Clinical formulation research
The RECONNECT publication reports two randomized studies of a defined clinical bremelanotide formulation. These studies concern a specified medicine and population, not Mytide's research material. Results from a clinical formulation cannot be transferred to an unapproved research vial.
Research evidence at a glance
| Research area | Example model or source | What it can tell you | Important limitation |
|---|---|---|---|
| Receptor pharmacology | FDA nonclinical review | Receptor binding and activity described for bremelanotide | An assay result is not a whole-system outcome |
| Behavioral research | Published rat study | Responses measured in that model | Animal findings do not establish human outcomes |
| Clinical formulation | RECONNECT trials | Results for a defined formulation and study population | Does not assess or approve Mytide's research vial |
PT-141 and Melanotan II: how do they compare?
Both names appear in melanocortin research, but they identify different compounds. Choose the material named in the research order; do not substitute one simply because their descriptions overlap. Mytide's product pages listed the following single-vial prices on November 20, 2026; prices and stock can change.
| Listing | Labeled form and amount | Listed price | Identity |
|---|---|---|---|
| PT-141 | 10 mg freeze-dried vial | $63 | PT-141 / bremelanotide |
| Melanotan II | 10 mg freeze-dried vial | $60 | A distinct compound |
Laboratory handling and storage
Follow the product's current documentation and your institution's written laboratory procedures for receipt, storage and handling. Record the product name, lot and condition on arrival, and consult the supplier if a document or storage requirement is unclear. This overview does not provide preparation or administration instructions.
Regulatory and research-use context
Mytide's PT-141 is sold for laboratory research only, not for human or animal consumption. Vyleesi is a separately regulated prescription formulation; its FDA approval does not approve a research vial. Requirements vary by jurisdiction and intended use, so purchasers should consult the applicable rules for their institution rather than infer status from a product name.
How to evaluate a supplier and certificate of analysis
Start with the exact compound name, labeled amount, supplied form and lot identifier. Then compare the lot identifier on the vial or order record with the report. Check what each test actually measures: identity, analytical purity, content and other tests answer different questions. A purity percentage alone is not proof of sterility, dosage, clinical suitability or every other quality attribute.
Mytide links a PT-141 certificate of analysis from United Laboratories reporting 99.54% purity for documented lot A1015. That result is specific to the documented lot and test. See how to read a peptide COA for a closer look at the report.
What remains uncertain?
Receptor studies, animal experiments and clinical trials answer different questions. Their results should not be pooled as if they were the same type of evidence. A published finding does not verify the identity, content or stability of a separately purchased vial. Likewise, a single lot's report cannot establish the specifications of every future lot. If a needed specification is not documented, request the relevant information before ordering.
Related PT-141 research and resources
- Background: PT-141 complete guide.
- Comparisons: PT-141 and other peptides.
- Testing: How to read a peptide COA.
- Product specifications and reports: PT-141 product page.
- Related compound: Melanotan II product page.
Common questions about PT-141 research
Is PT-141 the same as bremelanotide?
Yes. PT-141 is a research designation for bremelanotide. The compound name alone does not identify a finished product or make a research vial equivalent to a prescription medicine.
Is PT-141 the same as Melanotan II?
No. They are distinct compounds. Similar references to melanocortin receptors do not make them interchangeable.
What does a PT-141 purity result mean?
It describes the result of a specified analytical test on a documented sample. Check the method and lot; it does not independently establish every aspect of identity, content or safety.
Is Mytide's PT-141 FDA approved?
No. The FDA-approved prescription product is separate from Mytide's research vial. Approval of the medicine does not extend to the research product.
Where can I review PT-141 specifications before ordering?
The PT-141 product page lists the available size and links to documentation. Confirm the current lot, stock and price before placing a research order.
Ordering and documentation
View PT-141 and current product details, review the linked lab documentation and confirm the exact material and selected size. The product page describes domestic shipping and current availability. Browse the research catalog for other separately identified materials.
References
- Molinoff PB et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences, 2003.
- Pfaus JG et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences, 2004.
- Kingsberg SA et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology, 2019.
- US FDA. Vyleesi (bremelanotide) multidisciplinary review, 2019.
Explore PT-141 at Mytide Lab
Review product specifications and available lot documentation before ordering.
View PT-141